Documents

A list of downloadable documents created during development.

Breast cancer (metastatic) - bevacizumab (1st line, with capecitabine): equality impact assessment - guidance development

Breast cancer (metastatic) - bevacizumab (1st line, with capecitabine): final appraisal determination

Breast cancer (metastatic) - bevacizumab (1st line, with capecitabine): appraisal consultation

Breast cancer (metastatic) - bevacizumab (1st line, with capecitabine): EIA - scoping

Breast cancer (metastatic) - bevacizumab (1st line, with capecitabine): final scope

Breast cancer (metastatic) - bevacizumab (1st line, with capecitabine): final matrix

Breast cancer (metastatic) - bevacizumab (1st line, with capecitabine): institute's response to consultee and commentator comments on the draft scope

Breast cancer (metastatic) - bevacizumab (1st line, with capecitabine): Institute's response to consultee and commentator comments on the draft matrix

Breast cancer (metastatic) - bevacizumab (1st line, with capecitabine): draft scope

Breast cancer (metastatic) - bevacizumab (1st line, with capecitabine): provisional matrix

Breast cancer (first line) - bevacizumab: final scope

Breast cancer (first line) - bevacizumab: final matrix of consultees and commentators

Breast cancer (first line) - bevacizumab: Institute's response to consultee and commentator comments on the draft scope

Breast cancer (first line) - bevacizumab: Institute's response to consultee and commentator comments on the provisional matrix

Breast cancer (first line) - bevacizumab: draft scope (for second consultation)

Breast cancer (first line) - bevacizumab: provisional matrix (for second consultation)

Breast cancer (first line) - bevacizumab: draft scope

Breast cancer (first line) - bevacizumab: provisional matrix